ABSTRACT
INTRODUCTION
hrombocytopenia is commonly defined as a platelet count of <150×10 9 /L [1] . Some authors apply a cut off of 100 ×10 9 /L for ICU patients [2] , and others further specify platelet counts of 50×10 9 /L as severe thrombocytopenia [3] . Absolute platelet counts alone are not sufficient to characterize thrombocytopenia in critically ill patients; also, the time course of platelet counts provides important information. For example, a platelet count decline of > 50% compared to the baseline value can be normal after cardiac surgery, but if it occurs in the second week of ICU treatment, it may reflect pathologic platelet count courses [4] . This should prompt further diagnostic workup, even if the absolute platelet count is still within a range not associated with a substantial increase in the bleeding risk. The same applies if there is an absence of a platelet count rise within 5 days after ICU admission. Therefore, a comprehensive definition of thrombocytopenia in ICU patients should include the absolute platelet counts, platelet nadir, and course of the platelet count during the ICU stay [5] . Thrombocytopenia is well recognized in critically ill patients and is a risk factor for mortality.
A systematic review of thrombocytopenia in critically ill patients reported that its frequency varied widely, with some studies describing rates of more than 50%. Common limitations of the identified studies included variable definitions of thrombocytopenia, small sample sizes (many studies were single center) [3] . A low platelet count is a frequently encountered hematological abnormality in patients treated in intensive care units (ICUs). Although severe thrombocytopenia (platelet count <20 × 109/l) can be associated with bleeding, even moderate-degree thrombocytopenia is associated with organ failure and adverse prognosis. The etiology for thrombocytopenia in ICU is often multifactorial and correcting one etiology may not normalize the low platelet count [6] . Thrombocytopenia in ICU patients has been associated with adverse outcomes such as prolonged length of hospital stay and decreased survival. However, many of these studies were retrospective and performed in European or North American ICUs [7] . Because, the incidence and prognostic significance of new onset thrombocytopenia (NOT) in Asians is not known, Lim et al designed a study to investigate the incidence of NOT, including Heparin-Induced Thrombocytopenia (HIT), in a cohort of Korean medical ICU patients and to examine its impact on outcomes, they found that new onset thrombocytopenia was associated with longer ICU stay and increased mortality among Koreans.
One approach to identify potential causes of thrombocytopenia that require specific interventions is to consider the dynamics of platelet count changes. The relative decrease in platelet counts within the first 3 to 4 days after major surgery is informative about the magnitude of the trauma or blood loss, whereas the dynamic of the platelet count course thereafter shows whether or not the physiologic compensatory mechanisms are working. A slow and gradual fall in platelet counts developing over 5 to 7 days is more likely to be caused by consumptive coagulopathy or bone marrow failure, whereas any abrupt decrease (within 1-2 days) in platelet counts manifesting after an initial increase in platelet counts approximately 1 to 2 weeks after surgery strongly suggests immunologic causes, including heparin-induced thrombocytopenia, other drug induced immune thrombocytopenia, and post transfusion purpura [8] . Thrombocytopenia is common in ICU patients during the first 4 days and is correlated with the severity of the underlying illness or tissue damage. A poor prognosis is indicated by platelet counts that do not recover or show a progressive decrease 5 days after admission. The most common causes for a low platelet count in ICU patients are sepsis, massive tissue trauma, and DIC. Treatment should target the underlying disease. In most circumstances, the risk of bleeding associated with thrombocytopenia is lower than expected in critically ill patient sand platelet transfusions are only indicated in bleeding patients or before invasive interventions [5] . Thrombocytopenic patients have a higher prevalence of bleeding, greater transfusion requirements, a longer ICU stay, and higher mortality. Sequential measurements of platelet counts are readily available markers of disease progression. A drop in platelet count is an unfavorable prognostic sign and needs urgent clarification. In medical ICU patients, newly acquired thrombocytopenia is mostly associated with septic shock, bacteremia, or DIC [9] .
PATIENTS AND METHODS  This study was conducted in the Medical
Intensive Care Unit (MICU) of the Internal Medicine Department Zagazig University Hospitals, Egypt, in the period extending from March 2017 to March 2018.
The study included 400 patients admitted consecutively to MICU of internal medicine hospital in Zagazig university fulfilling the inclusion criteria, sixty-six patients were excluded from the study because of incomplete data (17 patients), loss of follow up within the ICU (24 patient . Thrombocytopenia is the most common coagulation disorder in the ICU with a prevalence of 15 to 60% depending on the cutoff used for defining thrombocytopenia (150 or 100 ×10 9 /L), studied population, duration and the course during ICU stay [10] . The incidence may also differ depending on the predominant clinical presentations dealt with in each ICU, that can vary in different centres (e.g. cardiac surgery centers versus liver transplantation units) and on the type of care provided (surgical, medical or mixed)
[1] . Many investigators evaluated the problem of thrombocytopenia in the critically ill patients and its impact on their outcomes among western countries, for example [11, 12, 13, 14] . Also some Asian studies were conducted for studying the same problem among Asian critical patients [7, 15] . Among Egyptian patients, the thrombocytopenia was studied in 2011 among small number of patients (70) admitted to Cairo university hospital with multiorgan failure [10] , also Mohammad et al [17] had evaluated thrombocytopenia and its impact on patients' outcomes among 50 patients admitted to respiratory intensive care unit (RICU) in Ain Shams university hospital, no other known studies had studied thrombocytopenia in Egyptian critical patients.
Because of the restricted locality (Cairo governorate) in Egypt and the restricted study sample (small number with specific illness) of the previous Egyptian studies, we have designed this study to determine the period prevalence of thrombocytopenia (both admission and newly occurring thrombocytopenia in ICU) among larger number of critically ill patients in Sharkia governorate admitted to our medical ICU in Zagazig university hospitals, those patients were admitted with different diagnoses, also we aimed to detect the pattern of this thrombocytopenia regarding the etiology, severity and timing of occurrence. Finally, we tried to determine the impact of thrombocytopenia on patients outcome and if it has a prognostic significance or not.
This prospective cohort study had been carried out in our medical ICU of internal medicine department in the period from March 2017 to March 2018. Out of 400 patients who were included in this study who were chosen consecutively during this period of time 41 patients were excluded due to incomplete data or loss of follow up and the remaining 359 patients were included in the study.
Our study revealed that the prevalence of thrombocytopenia (platelet count <150 ×109/L) among critically ill patients at admission is 36.8% and the new onset thrombocytopenia represents 15.8% giving the total prevalence of thrombocytopenia about 52.6%. Some previous studies had shown variable figures, Khurana et al [1] . (2017) revealed that thrombocytopenia in ICU (including both at time of admission and occurring in ICU stay) represents 37.6% of cases, while Lim et al [7] has found that the incidence of new-onset thrombocytopenia in ICU was 37.1% after exclusion of the patients with admission thrombocytopenia, while smaller incidence was determined in a large scale Canadian cohort study which was conducted in mixed coronary, medical, general and surgical ICUs, including 20,696 patients. This Canadian study showed prevalence of thrombocytopenia on admission in 13.3% of patients and incident thrombocytopenia, occurred during ICU stay, in 7.8% of patients [12] . This controversial result can be explained by studying thrombocytopenia at lower level (considering thrombocytopenia when platelet count <100 ×10 9 /L), resulting in considering all patients with mild thrombocytopenia (platelet count between 150 ×10 9 /L and 100 ×10 9 /L) as nonthrombocytopenic in that study [12] . An Egyptian study, which was conducted in Ain Shams university in 2014 among patients admitted to a respiratory intensive care unit (RICU) (one category of ICU patients), showed an incidence of new onset thrombocytopenia of 20% (10/50 cases) after exclusion of the patients with thrombocytopenia on admission [17] . [18] detected that 41% of the patients admitted to medical ICU reported thrombocytopenia (platelet count <150 ×10 9 /L) during their ICU stay at least once. So, the prevalence of thrombocytopenia is different in different ICU according not only to patients' number but also due to the underlying disease of admission and different drugs that are used during ICU stay, so we have to look for the drug that may affect platelet count in ICU.
Vanderschueren et al
We found in our study that the majority (80%) of patients admitted with thrombocytopenia had mild or moderate thrombocytopenia (platelet count ≥50 ×10 9 /L), while the remaining (20%) of patients had severe or very severe admission thrombocytopenia (platelet count <50×10 9 /L or <20×10 9 /L respectively) and in those developed new onset thrombocytopenia during their ICU stay, 87.7% of them had mild or moderate thrombocytopenia, while 12.3% of them had severe or very severe thrombocytopenia. Generally, platelet count <50 ×10 9 /L (severe and very severe thrombocytopenia) was found in 9.2% (33/359) of our study patients.
Comparable results were found in previous study by Marco-Schulke et al [19] , who found that the prevalence of severe thrombocytopenia (platelet count <50 ×10 9 /L) among critically ill patients was 6.3% (37 of 587 cases) and its incidence was associated with serum albumin level, serum bilirubin level and sepsis, also Stanworth et al [3] found in a multicenter observational study in UK that severe thrombocytopenia (platelet count <50×10 9 /L) documented in about 4.1% (78/1881) of critically ill patients in the first 24 hour of ICU admission, and Mark et al [20] had detected severe thrombocytopenia in 3.5% of their critical patients. Different result was detected by Vandijck et al [11] , who found that 41.8% of their patient with thrombocytopenia had platelet count <50×10 9 /L (thrombocytopenia was severe in 28.4% and very severe in 13.4%), this different result most probably was due to different nature of admission disease, they selected patients with documented nosocomial bloodstream infection so the prevalence of sepsis among those patients was very high.
In our study we found that liver cirrhosis with hypersplenism, sepsis and bone marrow disease were the commonest causes of admission thrombocytopenia (65.2%, 18.2% and 7.6% respectively), the same causes (but in different order) were found by Vanderschueren et al [18] , who had found that sepsis, liver disease with hypersplenism, primary hematologic disorder and medication (other than cytotoxic drugs) were the Maan et al [16] stated that the prevalence of thrombocytopenia in chronic liver diseases ranges from 6 % among non-cirrhotic patients with chronic liver disease to 70 % among patients with liver cirrhosis, so the high percentage of liver cirrhosis (65.2%) as a cause of admission thrombocytopenia was due to the high prevalence of liver cirrhosis among our study egyptian patients including those admitted due to complications of liver cell failure (27.6%) or any other medical emergency, these complications included hepatic encephalopathy, variceal bleeding and hepatorenal syndrome (HRS) (14.2%, 12.5% and 0.8% respectively).
The frequency of thrombocytopenia among 100 Egyptian patients with chronic hepatitis C virus as studied by Mohamed [21] was 24/100 (24%), mild thrombocytopenia was the commonest grade (17%) then moderate one (6%) and lastly severe thrombocytopenia (1%). The percentages of different thrombocytopenia grades are higher among the decompensated cirrhotic patients of our study who were constituting high percentage of patients admitted either due to liver cirrhosis complication (variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis or hepatorenal syndrome) or any other medical emergency.
In this study we found that the mortality rate among all patients with thrombocytopenia was 42.9% (35.6% in patients with admission thrombocytopenia and 59.6% in patients who developed thrombocytopenia during ICU stay), similar to our results, the mortality rate in critically ill patients with thrombocytopenia was found to be 44% (22/50) by Khurana and Deoke [15] , also Lim et al [7] detected that mortality rate among those who developed new onset thrombocytopenia was 36.2% compared to a rate of 10.3% among the nonthrombocytopenic patients in their Korean study. In most previous studies there was generally an association between thrombocytopenia and increased ICU mortality rate [4,12,17] . In our study there was no significant impact for thrombocytopenia in general on ICU stay and mortality compared to patients with normal platelet count, while we found that total thrombocytopenia (both admission thrombocytopenia and new onset thrombocytopenia) had slightly increased (RR) of mortality by 1.3 folds than those with persistently normal platelet count. Similar results were found by Dunaiceva et al [22] . We found that there is no impact of admission thrombocytopenia among our patients on ICU stay duration and ICU mortality compared to patients with normal platelet count (7.5±6 VS 8.9±7.9 and 35.6% VS 34.1%, P=0.09 & 0.788 respectively), also we did not find any increase in relative risk (RR) of mortality in admission thrombocytopenia (AT) patients compared to those with persistently normal platelet count. In contrast to our results, Hariharan and Paddle [23] found that there is a correlation between low admission platelet counts and adverse outcome, and they have demonstrated that the correlation between platelet count and predicted mortality exists across the spectrum of platelet values. This different result may be due to different patients' characteristics and main causes of admission. In our study the prevalence of chronic liver disease was high and it was responsible for most cases of admission thrombocytopenia, that was not found in Hariharan and Paddle study.
The current study identified that NOT was associated with longer ICU stay and higher ICU mortality rate compared to both admission thrombocytopenia (AT) and normal platelet count, also we found that [20] , Elgohary et al [10] and Lim et al [7] who identified that NOT was associated with longer ICU stay and higher ICU mortality when compared to patients without thrombocytopenia. In contrast to our results, Khurana and Deoke [15] found statistically insignificant higher mortality rate among patients who had thrombocytopenia on admission (AT) than those who developed it later during hospital stay (NOT), out of 39 patients who presented with thrombocytopenia on admission, 19 patients (48%) died during the hospitalization and those who developed thrombocytopenia later on during the hospitalization mortality rate was 27.3% among them (P = 0.20).
Also, Vanderschueren et al [18] found that 18 of 193 patients (9.3%) who never became thrombocytopenic died in the ICU vs. 31 of 89 patients (34.8%) who were thrombocytopenic at admission (p ˂0.001) and vs. 15 of 47 patients (31.9%) who developed thrombocytopenia during ICU stay (p = 0.002), but there was insignificant difference between thrombocytopenic at admission and those with NOT regarding mortality rate. The difference between our results and that obtained by others may be due to their small sample size of their study (50 patients) and also the difference in causes of admission as most of our patients had chronic liver disease.
Furthermore, our study revealed that the late occurrence of NOT (after 48 hours of admission) was associated with poorer outcome including longer ICU stay (8.7 VS 16.5 days, P=0.008) and higher rate of ICU mortality (69.2% VS 38.9%, P=0.03) when compared to early onset NOT (within 48 hours of admission), also we found that late NOT increased (RR) of mortality by 1.8 fold than early NOT. This comparison between early and late thrombocytopenia during ICU stay was done before by Akca et al [24] when they found that late thrombocytopenia is more predictive of death than early thrombocytopenia.
In our study we detected that among causes of newly developed thrombocytopenia (NOT) sepsis was the commonest cause and also the cause associated with the highest mortality rate (78.3%) which is consistent with Lim et al [7] who stated that sepsis with DIC was the most frequent cause of NOT with 46 patients (66.7 %), followed by drug-induced thrombocytopenia (18.8%), HIT (2.9%), and liver disease (1.4%). In seven patients, the cause of thrombocytopenia could not be determined, in this study sepsis related thrombocytopenia had adverse outcome. This study has several limitations including: Lack of long term outcome assessment, Inclusion of patients with different diagnoses, specially patients with stroke who require long ICU stay. CONCLUSION Thrombocytopenia is a frequent laboratory finding among critically in patients, which is generally correlated to the severity of illness. Most cases of thrombocytopenia are detected at time of admission and the rest of them develop during ICU stay.
Among our Egyptian patients the most common cause of thrombocytopenia on admission is the chronic liver disease with liver cirrhosis, while the most common cause of thrombocytopenia which develop during ICU stay is sepsis.
Thrombocytopenia is generally associated with higher APACHE II score when compared to normal platelet count indicating that it is associated with higher degree of morbidity and expected higher mortality rate.
The admission thrombocytopenia was associated with shorter ICU stay without increased mortality in comparison with persistently normal platelet count, but patients who developed thrombocytopenia during ICU stay had longer durations of admission and higher mortality rate than both patients with admission thrombocytopenia and those with persistently normal platelet count.
The late onset of thrombocytopenia during ICU stay (during first 48 hours of admission) was associated with poorer outcome than its early onset.
Immediate detection of thrombocytopenia among critically ill patients specially that develop during ICU stay and proper urgent
